Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. The reporting period includes the full results of Immunex Corporation, acquired on July 15, 2002, which significantly expanded Amgen's product portfolio to include ENBREL®.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2003 |
Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2003 |
Six Months Ended June 30, 2002 |
|---|---|---|---|---|
| Total Revenues | $2,041.1 | $1,249.1 | $3,802.3 | $2,257.6 |
| Net Income | $607.2 | $412.4 | $1,100.5 | $753.3 |
| Diluted EPS | $0.45 | $0.38 | $0.82 | $0.70 |
| Operating Cash Flow | N/A | N/A | $1,720.5 | $1,124.6 |
| Cash & Equivalents | $1,070.5 | N/A | $1,070.5 | N/A |
| Marketable Securities | $3,914.9 | N/A | $3,914.9 | N/A |
| Total Debt (Long-term + Current) | $3,086.7 | N/A | $3,086.7 | N/A |
Note: Operating cash flow and balance sheet items are presented for the six-month period or as of the period end date where applicable.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 63% for the three months and 68% for the six months ended June 30, 2003, compared to the prior year. Product sales rose 72% (quarterly) and 76% (six-month) driven principally by ENBREL®, Aranesp®, and Neulasta™.
- Profitability: Net income increased 47% (quarterly) and 46% (six-month). Operating income rose 45% and 45% respectively.
- Expense Increases:
- R&D Expenses: Increased 69% (quarterly) and 70% (six-month) due to higher staff costs (including Immunex integration), outside R&D costs, and clinical trials.
- SG&A Expenses: Increased 41% (quarterly) and 49% (six-month) driven by staff costs for new product launches and marketing expenses for ENBREL®.
- Amortization: $84.0 million (quarterly) and $167.9 million (six-month) recorded for intangible assets acquired from Immunex; no such expense was recorded in the comparable 2002 periods.
- Product Mix Shift: ENBREL® sales contributed $304.0 million (quarterly) and $578.0 million (six-month), representing a new revenue stream not present in the prior year. Conversely, NEUPOGEN® sales declined 9% (quarterly) and 14% (six-month) due to patient conversion to Neulasta™.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates 2003 capital spending to be between $1.3 billion and $1.5 billion, reflecting investments in the Rhode Island manufacturing plant, Puerto Rico expansion, and the Seattle research center.
- Future Growth Drivers: Expected growth is driven by Aranesp®, ENBREL®, and Neulasta™. ENBREL® sales are expected to benefit from new indications (ankylosing spondylitis) and expanded manufacturing capacity.
- Reimbursement Risks:
- Aranesp®: Effective Jan 1, 2003, CMS reduced reimbursement rates for Aranesp® in the hospital outpatient setting. Amgen disputes the accuracy of the rule but notes potential impact on sales.
- EPOGEN®: Future growth may be affected by federal reimbursement rate changes for end-stage renal disease patients.
- Supply Chain Risks: ENBREL® supply is dependent on third-party manufacturer Boehringer Ingelheim Pharma KG (BI Pharma) and Amgen's Rhode Island facility. Supply constraints could materially affect sales.
- Legal Proceedings:
- Johnson & Johnson Arbitration: Amgen received a $74.0 million award for costs and expenses in May 2003, recorded as a benefit in "Other items, net."
- Patent Litigation: Ongoing lawsuits regarding erythropoietin patents against Transkaryotic Therapies and Aventis.
- Stock Repurchases: The company repurchased 15.5 million shares for $899.6 million in the first six months of 2003. Approximately $942.5 million remains available under the current authorization through June 2004.
Investor Verification Checklist
- ENBREL® Supply Capacity: Verify the status of the Rhode Island facility and BI Pharma production schedules to ensure no supply constraints will limit sales growth.
- Reimbursement Policy Impact: Monitor the outcome of Amgen's challenge to the CMS reimbursement rule for Aranesp® and potential ripple effects on other payors.
- NEUPOGEN® Conversion Rate: Assess the rate of patient conversion from NEUPOGEN® to Neulasta™ to understand the trajectory of legacy product decline versus new product growth.
- Immunex Integration Costs: Review the trajectory of restructuring costs and amortization of intangible assets to gauge their impact on future operating margins.
- Capital Expenditure Execution: Confirm that the planned $1.3–$1.5 billion in capital spending is on track to meet future manufacturing demands.